HRS-9563 / Jiangsu Hengrui Pharma - LARVOL DELTA

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension (clinicaltrials.gov) - P2 | N=234 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension (clinicaltrials.gov) - P2 | N=234 | Not yet recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P2 trial • Cardiovascular • Hypertension

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study. (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

New P1 trial • Cardiovascular • Hypertension